| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Cash and cash equivalents | 3,669 | 5,741 | 8,496 | |
| Short-term investments | 89,732 | 101,829 | 116,385 | |
| Prepaid expenses and other current assets | 2,900 | 3,834 | 2,837 | |
| Total current assets | 96,301 | 111,404 | 127,718 | |
| Operating lease asset, net | 694 | 773 | 850 | |
| In-process research and development | 32,386 | 32,386 | 32,386 | |
| Other assets | 476 | 346 | 354 | |
| Total assets | 129,857 | 144,909 | 161,308 | |
| Accounts payable | 4,627 | 5,831 | 2,901 | |
| Current operating lease liabilities | 346 | 336 | 325 | |
| Accrued expenses and other liabilities | 9,323 | 7,552 | 5,959 | |
| Total current liabilities | 14,296 | 13,719 | 9,185 | |
| Deferred tax liabilities | 2,183 | 2,183 | 2,183 | |
| Non-current operating lease liabilities | 376 | 467 | 555 | |
| Warrant liabilities | 21,948 | 22,512 | 34,805 | |
| Total liabilities | 38,803 | 38,881 | 46,728 | |
| Preferred stock, value-Series XNon Voting Convertible Preferred Stock | - | - | 0 | |
| Convertible preferred stock, value-Series X1Non Voting Convertible Preferred Stock | 53,543 | 53,543 | 53,543 | |
| Preferred stock, value-Series X1Non Voting Convertible Preferred Stock | - | - | 0 | |
| Convertible preferred stock, value-Series XNon Voting Convertible Preferred Stock | 2,151 | 2,151 | 2,151 | |
| Common stock, 0.001 par value, 300,000,000 shares authorized at september 30, 2025 and 200,000,000 at december 31, 2024 59,881,775 and 59,789,275 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 60 | 60 | 60 | |
| Retained Earnings Accumulated Deficit | - | - | -362,081 | |
| Additional paid-in capital | 426,047 | 423,619 | 420,925 | |
| Accumulated other comprehensive income | 9 | -48 | -18 | |
| Accumulated deficit | -390,756 | -373,297 | -362,100 | |
| Total stockholders equity | 35,360 | 50,334 | 58,886 | |
| Total liabilities, convertible preferred stock and stockholders' equity | 129,857 | 144,909 | 161,308 | |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)